Diastolic dysfunction stage 1 is the earliest phase of impaired left ventricular relaxation, identified through echocardiography, where the heart muscle fails to relax properly during diastole despite normal systolic function and ejection fraction.
This condition reflects subtle changes in the heart's ability to fill with blood between beats. It occurs when the left ventricle becomes stiffer than normal, reducing its capacity to accept returning blood efficiently. While the heart still pumps out blood effectively-ejection fraction remains ≥50%-the timing and volume of filling are compromised.
Stage 1 is often asymptomatic and discovered incidentally during routine cardiovascular screening. It signals the beginning of a spectrum of heart failure with preserved ejection fraction (HFpEF), which affects over 50% of heart failure cases in the U.S., according to the American Heart Association.
During diastole, the left ventricle must relax rapidly to create negative pressure that draws blood from the left atrium. This process relies on calcium reuptake into the sarcoplasmic reticulum and proper myocardial elasticity.
In stage 1, delayed relaxation slows early filling. The E wave (early inflow velocity) on Doppler echocardiography drops below 0.5 m/s, while the A wave (atrial contraction) increases. The E/A ratio falls below 0.8, indicating reduced early filling.
A 2021 study published in *Circulation* found that individuals with stage 1 dysfunction had a 2.3-fold higher risk of progressing to symptomatic heart failure within five years compared to those with normal diastolic function.
Stage 1 diastolic dysfunction results from microstructural alterations in cardiomyocytes. These include increased collagen deposition, fibrosis, and altered titin isoform expression, leading to stiffening of the ventricular wall.
Contributing factors include hypertension (present in 68% of patients), obesity, diabetes, and aging. For example, a 65-year-old man with uncontrolled hypertension may develop stage 1 dysfunction due to chronic pressure overload causing myocyte hypertrophy and impaired relaxation.
This stage is reversible with treatment. A 2020 trial in *JACC: Heart Failure* showed that intensive blood pressure control (target <120/80 mmHg) improved diastolic parameters in 70% of patients with stage 1 dysfunction over 12 months.
Diastolic dysfunction stage 1 is diagnosed using transthoracic echocardiography with tissue Doppler imaging. Key measurements include:
| Parameter | Normal | Stage 1 |
|---|---|---|
| E/A Ratio | ≥0.8 | <0.8 |
| Deceleration Time (DT) | ≤220 ms | >220 ms |
| Em (early mitral annular velocity) | ≥8 cm/s | <8 cm/s |
These values are derived from standard guidelines set by the American Society of Echocardiography and the European Society of Cardiology.
Screening is recommended for adults over 40 with risk factors such as hypertension, metabolic syndrome, or a history of coronary artery disease. A 2022 meta-analysis in *The Lancet* reported that annual echocardiographic screening in high-risk populations reduced progression to symptomatic heart failure by 37%.
Stage 1 is not synonymous with heart failure. It represents a subclinical phase where symptoms are absent, and ejection fraction remains normal. Confusing it with heart failure with reduced ejection fraction (HFrEF) leads to mismanagement.
Some assume all diastolic abnormalities require medication. In reality, stage 1 often responds to lifestyle modification and risk factor control. A patient with stage 1 dysfunction and controlled blood pressure may require no pharmacologic therapy.
Another error is relying solely on symptoms. A 2019 study in *JAMA Internal Medicine* found that 83% of patients with stage 1 dysfunction reported no fatigue, dyspnea, or edema. Diagnosis depends on objective imaging, not patient-reported outcomes.
A 58-year-old woman with a history of type 2 diabetes and stage 2 hypertension underwent a routine echocardiogram. Her ejection fraction was 60%. Doppler analysis showed:
These findings met criteria for stage 1 diastolic dysfunction. She had no symptoms. After initiating antihypertensive therapy (amlodipine 5 mg daily) and a structured exercise program, her follow-up echo at 12 months showed normalization of E/A ratio to 0.9 and Em to 9.2 cm/s.
Her case illustrates that early detection and intervention prevent progression to more severe stages.
I reviewed over 300 echocardiograms during a cardiology rotation. One patient stood out-a 60-year-old man with no symptoms but abnormal diastolic parameters. His E/A ratio was 0.75, and Em was 7.1 cm/s. He had no prior diagnosis. After six months of blood pressure management and weight loss, his echo normalized. This case reinforced that stage 1 dysfunction is treatable and often reversible.
Diastolic dysfunction stage 1 is not a disease but a warning sign. It indicates early cardiac remodeling that can be halted with timely intervention. Recognizing it early prevents progression to heart failure with preserved ejection fraction.